It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Residential buildings can concentrate radioactive radon gas, exposing occupants to particle radiation that increases lung cancer risk. This has worsened over time in North America, with newer residences containing greater radon. Using data from 18,971 Canadian households, we calculated annual particle radiation dose rates due to long term residential radon exposure, and examined this as a function of occupant demographics. The current particle radiation dose rate to lungs from residential radon in Canada is 4.08 mSv/y from 108.2 Bq/m3, with 23.4% receiving 100–2655 mSv doses that are known to elevate human cancer risk. Notably, residences built in the twenty-first century are occupied by significantly younger people experiencing greater radiation dose rates from radon (mean age of 46 at 5.01 mSv/y), relative to older groups more likely to occupy twentieth century-built properties (mean age of 53 at 3.45–4.22 mSv/y). Newer, higher radon-containing properties are also more likely to have minors, pregnant women and an overall higher number of occupants living there full time. As younger age-of-exposure to radon equates to greater lifetime lung cancer risk, these data reveal a worst case scenario of exposure bias. This is of concern as, if it continues, it forecasts serious future increases in radon-induced lung cancer in younger people.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Saskatchewan, Faculty of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
2 University of Calgary, Robson DNA Science Centre, Departments of Biochemistry and Molecular Biology and Oncology, Charbonneau Cancer Institute, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
3 University of Calgary, School of Architecture and Landscape Planning, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
4 University of Calgary, Departments of Cancer Epidemiology and Prevention Research and Community Health Sciences, Charbonneau Cancer Institute, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
5 University of Calgary, Division of Psychosocial Oncology, Department of Oncology Charbonneau Cancer Institute, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)